Puma Biotechnology Presents Interim Results from the Phase 2 Trial Evaluating Neratinib for HER2 Mutant Metastatic Cervical Cancer

Puma Biotechnology Presents Interim Results from the Phase 2 Trial Evaluating Neratinib for HER2 Mutant, Metastatic Cervical Cancer

10:51 EDT 19 Mar 2019 | Speciality Pharma Journal

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting in Honolulu, Hawaii. “Neratinib in patients with …

More From BioPortfolio on "Puma Biotechnology Presents Interim Results from the Phase 2 Trial Evaluating Neratinib for HER2 Mutant, Metastatic Cervical Cancer"